Nasal Drug Delivery Market
Intranasal Therapeutics Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Indication (Acute Repetitive Clusters, Anaphylaxis, COVID-19, Dry Eye Disease, Hypoglycemia, Influenza, Major Depressive Disorder, Migraine, Nasal Polyps and Prader-Willi Syndrome), Type of Molecule (Biologics and Small Molecule), Type of Drug and Geographical Regions
-
Lowest Price Guaranteed
-
Pages
252 -
Last Updated
September 2026 -
View Count
17534 -
-At present, 19 start-ups are driving innovation in this domain; various R&D initiatives have been undertaken by these players over the last few years
What is the Global Intranasal Therapeutics Market Size?
The global nasal drug delivery market, valued at USD 6.1 billion in 2025, is projected to reach USD 8.1 billion in 2026 and USD 26.8 billion by 2035, with a 14.2% CAGR during the forecast period 2026 to 2035.
 |
To learn more about this report, request a free sample copy
With the rise in chronic diseases, increased demand for non-invasive drug delivery systems and preference for self-administering medications, nasal drug delivery is gaining more momentum as a preferred option. Pharmaceutical Spray Drying complements these formulation approaches by converting liquid feeds into engineered powders with controlled particle and stability characteristics. Further, this type of delivery helps in circumventing the challenge associated with drug delivery through the blood brain barrier (BBB), which hinders the entry of the target drug into the CNS, acting as a significant roadblock in the development of effective treatment modalities.
 |
 |
 |
In addition, the healthcare costs associated with chronic disease are likely to reach $47 trillion, worldwide, by 2030. As a result, stakeholders in the pharmaceutical domain have shifted their focus towards the use of intranasal treatments, which have demonstrated to be capable of bypassing the blood brain barrier, thereby, delivering the target drug directly into the brain.
 |
 |
 |
In this context, industry stakeholders are actively developing / marketing intranasal drugs. Notable examples of intranasal COVID-19 targeting drugs across different phases of development include (in alphabetical order) COVIDROPS™, DEXANEUROSONE™ and Zavegepant with proven pharmacological value and favorable safety profiles.
 |
 |
 |
Despite the several advantages offered by the intranasal route of administration, the delivery of therapies via the aforementioned approach is associated with some challenges, such as mucus and epithelial barriers, low bioavailability of drugs, limited drug absorption and shorter residence time. Most of these concerns can be mitigated via the use of targeted drug delivery device.
Nasal Drug Delivery Market: Report Attributes
| Key Report Attributes | Details | |
| Historical Trend | Since 2023 | |
| Forecast Period | Till 2035 | |
| Market Size in 2026 | $ 8.1 Billion | |
| Market Size in 2035 | $ 26.8 Billion | |
| CAGR (Till 2035) | 14.2% | |
The market report also features the likely distribution of the current and forecasted opportunity within the nasal drug delivery market across various segments, such as target indication, type of molecule, type of drug and geographical regions.
In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s growth.
At present, close to 40 intranasal drug delivery systems are available in the market. Additionally, several stakeholders have undertaken multiple partnerships and collaboration initiatives for the development of novel intranasal drug delivery systems.
What are the Recent Developments in the Nasal Drug Delivery Market ?
Several recent developments in the field of nasal drug delivery market services have occurred, and we outline some of these below. These developments, even if they arose after our market report’s release, support the overall nasal drug delivery market trends detailed in our analysis.
- In March 2026, the FDA approved an updated label for ARS Pharmaceuticals' neffy (epinephrine nasal spray) 1 mg, removing the age restriction. This allows its use in all patients weighing at least 15 kg, regardless of age, expanding needle-free anaphylaxis treatment access for younger children.
- In February 2026, Emergent BioSolutions received the FDA approval for a supplemental New Drug Application (sNDA) introducing new multipack configurations of over-the-counter NARCAN Nasal Spray. These are designed to meet the needs of community programs and organizations distributing large quantities to combat opioid overdoses.
- In November 2025, Aptar Pharma announced the acquisition of technology assets from SipNose in order to expand its intranasal drug delivery portfolio with focus on nose-to-brain and central nervous system applications.
- In February 2025, Zeteo Biomedical launched ZTech-P CygnusMR™ and CygnusSDX™ delivery devices for precise, metered-unit dosing of dry powder drugs and biologics via nasal and nose-to-brain administration, providing needle-free solutions to accelerate pharmaceutical development and commercial deployment of nasal combination products.
- In January 2025, Johnson & Johnson announced FDA approval of SPRAVATO® as the first and only monotherapy for adults with major depressive disorder.
Nasal Drug Delivery Market Segmentation Insights
The market research report presents an in-depth analysis of the various nasal drug delivery companies, across different segments, as defined in the table below:
Nasal Drug Delivery Market: Market Segmentations
| Market Segmentations | Details | |
| Target Indication |
|
|
| Type of Molecule |
|
|
| Type of Drug |
|
|
| Geographical Regions |
|
|
Driven by the increasing in demand for non-invasive therapies, the nasal drug delivery market is likely to witness steady growth in the coming years.
How is the Nasal Drug Delivery Market Segmented?
Market Share by Target Indication: Dry Eye Disease Hold the Largest Share
- The global market highlights the market segmentation of nasal drug delivery, based upon their target indication into acute repetitive clusters, anaphylaxis, COVID-19, dry eye disease, hypoglycemia, influenza, major depressive disorder, migraine, nasal polyps, and prader-willi syndrome. In 2025, dry eye disease segment obtains the highest (60%) of the nasal drug delivery market share. This is likely due to the widespread prevalence of dry eye syndrome and the advantages of nasal delivery systems in treating dry eye disease.
- The nasal polyps segment is likely to be the fastest growing segment in this industry, with annualized growth rate (CAGR) of over 7% during the forecast period.
Market Share by Type of Molecule: Small Molecules are Dominating the Market
- The global market highlights the market segmentation of nasal drug delivery, based upon the type of molecule, which includes biologics and small molecules. In 2025, the small molecules capture the maximum number (95%) of the market share and are likely to continue dominating the market by 2035. This dominance is due to their versatility, enhanced absorption, and established regulatory approval pathways.
- Biologics are expected to be the fastest growing segment in this industry, with annualized growth rate of (22%) till 2035.
Market Share by Geographical Regions : Asia-Pacific to Propel in the Nasal Drug Delivery Sector in the Coming Years
- This segment highlights the distribution of nasal drug delivery market across various geographies, such as North America, Europe, Asia-Pacific, Latin America and Middle East and North Africa. According to our projections, North America is likely to capture the majority (45%) of the nasal drug delivery market share in 2025, and this trend is unlikely to change in the future.
- It is worth highlighting that the market in Asia-Pacific is likely to grow at a relatively higher CAGR (20%), during the forecast period. This is a result of the expanding patient population, the growing number of diseases including neurological disorders, and the mounting demand for effective therapeutics.
Nasal Drug Delivery Market: Report Deliverables
| Report Deliverables | Details | |
| Excel Data Packs |
|
|
| Key Nasal Drug Delivery |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope |
15% Customization |
|
What are the Major Takeaways of Nasal Drug Delivery Market ?
The “Nasal Drug Delivery Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the companies involved in development of nasal drug delivery technologies and intranasal therapeutics.
How is the Competitive Landscape of Nasal Drug Delivery Market Fragmented?
Several small, large, and very large companies are present in the nasal drug delivery market. Currently, 19 startup companies are serving in the market and constantly striving and initiating R&D for novel drug delivery systems.
Furthermore, to build a competitive edge, leading companies are expanding their portfolio by showcasing the uniqueness of their proprietary intranasal drug delivery system and experimenting with putting drugs or biologics together with devices.
Some of these start-ups include Belhaven Biopharma, Pulmonem, Lyra Therapeutics and others.
Market Drivers Analysis: Upsurge in Patient Population to Accelerate the Market Growth
The nasal drug delivery market is likely to witness substantial growth driven by various factors. One of the major factors contributing to the market demand includes the increasing number of patients with multiple diseases such as acute repetitive clusters, anaphylaxis, COVID-19, dry eye disease, hypoglycemia, and influenza, coupled with the mounting demand for effective therapeutics.
Primarily, the benefits of nasal drug delivery such as its non-invasive route of administration for elderly and pediatric patients as compared to oral medication or injections, further contribute to growing demand for such therapeutics. Besides, ongoing technological advancements and growing regulatory support are also likely to drive nasal drug delivery market growth in the future.
Key Market Trends in Nasal Drug Delivery Market
Patent Analysis in Nasal Drug Delivery Market: Nearly 410 Patent Applications Have been Filed to Secure Intellectual Property
Recently, stakeholders have filed nearly 410 patent applications to protect intellectual property in this domain. According to the type of patents, the majority (77%) were patent applications and approximately 19% were granted patents.
Despite the high number of patents, very few belong to the high-value category. According to our analysis, 8.82% of patents have the highest relative valuation.
Trends Analysis in Nasal Drug Delivery Market: Increasing Partnership & Collaboration to Foster Market Prospect
One of the latest trends in the nasal drug delivery market is the growing number of collaborations and partnerships, which have significantly boosted the market growth through continuous technological advancements. This innovation has spurred the interest of industry players, encouraging the development of novel drug delivery systems.
Stakeholders engaged in this domain have signed numerous agreements, with product development and commercialization agreements accounting for the largest share, around 24%. One of the recent agreements include the partnership between Orexo and Abera for the development of nasal powder vaccines based on the drug delivery technology AmorphOX.
Regional Analysis: North America is Anticipated to Lead the Market with Soaring Revenue Generated
In respect of regional insights, North America captures 85% of the global market share in 2035. With the largest market share, North America influences the nasal drug delivery market growth substantially. Various factors contribute to the region’s dominance.
Firstly, a rise in the cases of neurological disorders and infectious diseases is raising the market demand. Additionally, the presence of industry players particularly, emerging startup companies has significantly expanded the market potential. Interestingly, intranasal therapies targeting dry eye diseases are likely to capture the dominant share (64.8%) of the market (in terms of sales-based revenues) and this trend is unlikely to change in the foreseen future as well.
From the Author’s Desk
Author’s View on Nasal Drug Delivery Market
Driven by effective intranasal drug delivery through the integration of advanced technologies, resulting into improved drug absorption and efficacy of drugs at the target site, the nasal drug delivery market is likely to witness substantial growth in the coming years. Further, rise in usage of smart implants, 3D technology integrated into the drug delivery devices are likely to improve the safety and efficacy of the drugs administered.
Author’s Bio
Ankita Rana has been working as a competent business research analyst since she joined Roots Analysis. Throughout her dynamic tenure, Ankita Rana has made significant strides to evaluate emerging trends and technologies within the pharmaceutical industry, contributing critically to numerous comprehensive research reports that provide in-depth views on topics such as metaverse in healthcare market.
Glossary
- Nasal Drug Delivery: Administration of drug through the nasal cavity, where the medication is likely to absorb through the bloodstream for the treatment of various disease.
- Transdermal Drug Delivery: Administration of the drug through the skin for systemic distribution across the whole body.
- Target Indication: The specific drug for a particular disease treatment in order to target that particular tissue or organ.
- Blood Brain Barrier: Blood brain barrier refers to the endothelial lining of brain capillaries.